Background: Bullous pemphigoid is a cutaneous autoimmune blistering disorder.
Introduction
Bullous pemphigoid is a cutaneous autoimmune blistering disorder against the hemidesmosome, a part of the basement membrane that attaches the epidermis to the dermis. 1 The etiology for what precipitates this disease is not entirely clear at this point, although it has been associated with certain medications. It most commonly occurs in the elderly, especially ages 70 years and over, and has increased risk for mortality as well as long term morbidity. 2 Gliptins are a drug class that was first introduced into the market in 2006 to treat diabetes mellitus type 2. They work by competitively inhibiting the enzyme dipeptidyl peptidase IV (DPP-IV/CD26), which normally breaks down incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) that are released in response to a meal. By preventing GLP-1 and GIP inactivation, they are able to increase the secretion of insulin and suppress the release of glucagon by the pancreas. 3 Current medications on the market include sitagliptin, saxagliptin, linagliptin, and alogliptin in the United States, as well as vildagliptin in the UK. Vildagliptin was initially not approved by the FDA due to pre-clinical studies showing skin lesions in monkeys. 4 Since the release of gliptins into the market they have been linked to several skin reactions in humans, most serious of which is Steven Johnson syndrome. 5 The enzyme DDP-IV has been shown to be ubiquitously expressed in almost every organ system, including the skin. 6 
Case report
We describe the case of a 70-year-old male with a past medical history of diabetes type 2, developmental delay, chronic iron deficiency anemia, and hypertension. He had chronic right-sided weakness secondary to a large left middle cerebral artery stroke one-year prior. He was up to date on routine cancer screening and had no history of malignancy or prior autoimmune disease. The patient had developed a diffuse eruption of bullae largely on his arms, neck, chest, and groin. Many of the bullae were still intact upon presentation to our facility two weeks following its onset. Lesions presented on both erythematous and normal appearing areas of skin. The patient also complained of significant urticaria and had excoriations on his extensor surfaces, however the urticaria had developed after the appearance of the lesions. There was no evidence of mucosal involvement. His home medications included acetaminophen, aspirin, citalopram, docusate sodium, levothyroxine, lisinopril, metformin, oxybutynin, and simvastatin. He had previously been on sitagliptin 50 mg daily for one year prior to onset of the rash, and it was discontinued by a physician four days before transfer to our facility. A complete blood count upon transfer consisted of a white blood count of 8.6 K/μL, hemoglobin 10.5 g/dL, hematocrit 31.6%, and platelets 281,000/mm 3 . His differential was significant for 9% eosinophils (normal range is 1-4%). Electrolytes and liver function tests were all within normal limits. His Hemoglobin A1C was 7.1%. A skin biopsy was performed and direct immunofluorescent staining revealed a linear staining pattern with complement C3 and IgG at the subepidermal basement membrane zone consistent with bullous pemphigoid. The patient was started on methylprednisolone 60 mg IV every eight hours for 3 days and was transitioned to oral prednisone 60 mg daily (the equivalent of 0.75 mg/kg/day of the patient's body weight). The initial dosing of methylprednisolone was per the preference of the dermatologist. For the patient's diabetes, he was continued on his metformin as well as initiated on subcutaneous insulin. There was significant improvement of the rash after 2-3 days and he was discharged on a prednisone. He had sustained remission and no recurrence of the lesions 3 months later at which point his prednisone had been tapered off.
Review of the literature
There have been four reports that have explored the relationship between dipeptidyl peptidase-IV inhibitors and bullous pemphigoid. The first case series looked at five patients who received a DDP-IV inhibitor (sitagliptin and vildagliptin) as well as metformin who developed bullous pemphigoid with an onset range of 2-13 months. These patients improved after withdrawal of the suspected agent and relatively mild therapeutic intervention. Inhibition of DPP-IV by gliptins could promote eosinophil activation in the skin by a CCL11/exotaxin-mediated mechanism. 7, 14 Eosinophil activation is known to contribute significantly to blister formation in bullous pemphigoid. 1, 2, 14 Decreased levels of DPP-IV enzyme has also been associated with increased levels of transforming growth factor beta-1 (TGF beta 1) in T cells leading to its extracellular secretion.
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TGF beta 1 has previously been demonstrated to be elevated in bullous pemphigoid in the serum and not the blister fluid 16, 19 ; it's role in the serum has been postulated as a part of the Th3 regulatory component of the autoimmune reaction that inhibits further production of inflammatory cytokines like interferon gamma and interleukin 2.
15-17
The DPP-IV receptor, on the other hand, is felt to play an important role in the Th1 component of immunity. 13 Bullous pemphigoid has previously demonstrated a combination of Th1, Th2, and Th3 mediated immunity through the measurement of its various cytokines. The gliptin induced inhibition of the DDP-IV/CD26 mediated Th1 component of immunity, as well as the gliptin-induced increase in TGF beta 1 through Th3 regulatory mechanisms could promote a more balanced Th1, Th2, and Th3 cytokine profile, which is what bullous pemphigoid has consistently been shown to demonstrate. [17] [18] well to discontinuation of the therapy as well as treatment with steroids. 8 In the third report, three more cases were reported associated with gliptin usage. Two of the cases were associated with sitagliptin and one with vildagliptin. One of the cases is described in detail as having a striking temporal relationship between starting the gliptin and the subsequent development of bullous pemphigoid, as well as significant improvement with drug cessation and topical corticosteroids. 9 The fourth report was a study that looked at sitagliptin associated allergic reactions submitted to the Adverse Event Reports System database of the Food and Drug Administration from October 2006 to November 2008, which reported 26 cases of "serious skin reactions", two of which were Steven Johnson syndrome and two of which were toxic epidermal necrosis. The other 22 cases included a mix of dermatologic conditions that were described as "bullous, desquamative, blistering, exfoliative, urticarial, or exanthematous skin reactions". It was not defined what percentage of these represented bullous pemphigoid, but nevertheless emphasizes the relationship between serious skin reactions and gliptins. 5 It should be noted that in almost all cases the patients were taking metformin concurrently with the DDP-IV inhibitor, as this is a common regimen for treatment of diabetes. However, metformin has been on the market for many years and to date the literature is devoid of metformin-induced cases of bullous pemphigoid.
Discussion
The gliptins are a relatively new class of drug and have been known to cause adverse skin reactions as reviewed above. According to the Naranjo ADR probability scale, this patient's use of sitagliptin suggests that this is a "possible" reaction. 10 The patient did have other additional risk factors that have been independently associated with risk for bullous pemphigoid. According to a 2007 prospective case control study this patient's other risk factors included his age, low mini-mental state examination (severe cognitive impairment), and history of prior stroke. It should be noted that gliptins were introduced into the market in 2006 and would have not been included in this study.
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The other medications that the patient had been prescribed have not been strongly associated with drug induced bullous pemphigoid. Classic drugs associated with drug-induced BP include spironolactone, chloroquine, furosemide, and penicillin antibiotics. 1, 12, 20 While an association has been established between the dipeptidyl peptidase-IV inhibitors and bullous pemphigoid, the exact etiology has not been clearly defined. Dipeptidyl peptidase IV, also known as CD26, is a cell surface glycoprotein with intrinsic enzyme activity that is ubiquitously expressed throughout the body including the skin, but is also expressed in the brain, heart, intestine, kidney, lung, and lymphocytes. Decreased levels of DPP-IV enzyme has been found to correlate with disease severity of autoimmune diseases such as: Rheumatoid arthritis, systemic lupus erythematous, 
Conclusion
Our case and the findings from our literature review further demonstrate a link between dipeptidyl peptidase-IV inhibitors and the development of bullous pemphigoid. The exact mechanism at this time is unknown but is believed to be multifactorial involving many aspects of the immune system. Due to the morbidity and mortality associated with bullous pemphigoid, this link can help providers make more informed decisions on their own patients' medical regimens and avoid adverse drug reactions in at risk populations.
